IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.
Cristina Puig-SausGiulia ParisiAngel Garcia-DiazPaige E KrystofinskiSalemiz SandovalRuixue ZhangAmeya S ChamphekarJames McCabeGardenia C Cheung-LauNhat A TruongAgustin Vega-CrespoMarie Desiles S KomenanJia PangMignonette H MacabaliJustin D SacoJeffrey L GoodwinBrad BolonChristopher S SeetAmelie Montel-HagenGay M CrooksRoger P HollisBeatriz Campo-FernandezDaniela BischofKenneth CornettaEric H GschwengCelia AdelsonAlexander NguyenLili YangOwen N WitteDavid BaltimoreBegonya Comin-AnduixDonald B KohnXiaoyan WangPaula CabreraPaula J Kaplan-LefkoBeata Berent-MaozAntoni RibasPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Coadministration of HSCs and T cells expressing an NY-ESO-1 TCR is safe in preclinical models. The results presented in this article led to the FDA approval of IND 17471.